Cyclosporins

• 

  Subject Areas on Research

  • A pilot study of low-dose cyclosporin for graft-versus-host prophylaxis in marrow transplantation. 
  • A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. 
  • A synergistic effect of total lymphoid irradiation, cyclosporine, and splenectomy in a hamster-to-rat hepatic xenograft model. 
  • Acute and chronic graft-versus-host disease in man. 
  • Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. 
  • Allogeneic small bowel transplantation with cyclosporine and donor whole-body irradiation. 
  • Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. 
  • Assessment of purging with multidrug resistance (MDR) modulators and VP-16: results of long-term marrow culture. 
  • Association between cyclosporin neurotoxicity and hypomagnesaemia. 
  • Cadaveric renal transplantation in the cyclosporine and OKT3 eras: an update of the University of Wisconsin-Madison experience. 
  • Chronic graft-versus-host disease, obliterative bronchiolitis, and graft-versus-leukemia effect: case histories. 
  • Combined total lymphoid irradiation and cyclosporine promote xenograft survival. 
  • Cyclosporin-A increases synthesis of 1,25-dihydroxyvitamin D3 in the rat and mouse. 
  • Cyclosporine A inhibits Ca2+-dependent stimulation of the Na+/H+ antiport in human T cells. 
  • Cyclosporine augments receptor-mediated cellular Ca2+ fluxes in isolated hepatocytes. 
  • Cyclosporine inhibition of CH series murine B-cell lymphomas. 
  • Cyclosporine inhibition of a murine B cell lymphoma. 
  • Cyclosporine nephrotoxicity in cardiac allograft patients--a seven-year follow-up. 
  • Cyclosporine nephrotoxicity: a workshop to discuss mechanisms, diagnosis, and treatment. 
  • Cyclosporine therapy and the development of interstitial fibrosis in renal allografts. 
  • Cyclosporine treatment of chronic graft-versus-host disease following allogeneic bone marrow transplantation. 
  • Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. 
  • Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. 
  • Early and late forms of cyclosporine nephrotoxicity: studies in cardiac transplant recipients. 
  • Effect of cyclosporine on bile secretion in rats. 
  • Effect of steroid withdrawal on hypertension and cholesterol levels in living related recipients. 
  • Effects of cyclosporine in experimental cryptococcal meningitis. 
  • Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial. The Multiple Sclerosis Study Group. 
  • Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. 
  • Graft-versus-host disease prevention by methotrexate combined with cyclosporin compared to methotrexate alone in patients given marrow grafts for severe aplastic anaemia: long-term follow-up of a controlled trial. 
  • Graft-versus-host disease prophylaxis with methotrexate/cyclosporine in children with severe aplastic anemia treated with cyclophosphamide and HLA-identical marrow grafts. 
  • Hemolytic anemia is not a frequent complication of ABO unmatched renal allografts from living related donors. 
  • Identification of cyclosporin C from Amphichorda felina using a Cryptococcus neoformans differential temperature sensitivity assay. 
  • Improvements in digital vasculature observed using micro magnetic resonance angiography after high-dose immunosuppression for severe systemic sclerosis. 
  • Infection and cyclosporine. 
  • Inhibition of in vitro NZB antibody responses by cyclosporine. 
  • Inhibition of in vitro anti-DNA B-cell responses by cyclosporine. 
  • Isoflurane alters the kinetics of oral cyclosporine. 
  • Liver transplantation. 
  • Macrophage migration into hepatic xenografts in the hamster-to-rat combination. 
  • Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. 
  • Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. 
  • Minimal risk of chronic renal dysfunction in marrow transplant recipients treated with cyclosporine for 6 months. 
  • Modulation of etoposide (VP-16) cytotoxicity by verapamil or cyclosporine in multidrug-resistant human leukemic cell lines and normal bone marrow. 
  • Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis. 
  • Orthotopic liver transplantation in patients 60 years of age and older. 
  • Orthotopic liver transplantation in patients over 60 years of age. 
  • P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. 
  • Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia group B study 9420. 
  • Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. 
  • Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia. 
  • Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. 
  • Predictive factors for immunologic graft failure in cadaver renal transplant recipients. 
  • Prolonged heart xenograft survival using combined total lymphoid irradiation and cyclosporine. 
  • Prolonged survival of hepatic xenografts in the hamster to rat combination: efficacy of cyclosporine in combination with splenectomy. 
  • Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808. 
  • Renal failure in cardiac transplantation. 
  • Renal transplantation in the American black. 
  • Retina-specifically expressed novel subtypes of bovine cyclophilin. 
  • Significant prolongation of hamster liver transplant survival in Lewis rats by total-lymphoid irradiation, cyclosporine, and splenectomy. 
  • Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. 
  • The effect of 15-deoxyspergualin on hamster-to-rat cardiac xenograft survival. 
  • The effect of TLI and cyclosporine on xenograft survival. 
  • The effect of cyclosporine, total lymphoid irradiation, and cobra venom factor on hyperacute rejection. 
  • The importance of class I and class II HLA in cadaveric renal transplantation. 
  • The influence of RS-61443 on antibody-mediated rejection. 
  • The pathophysiology and treatment of graft-versus-host disease. 
  • The spectrum of ciclosporin nephrotoxicity. 
  • Thromboxane receptor blockade improves cyclosporine nephrotoxicity in rats. 
  • Total lymphoid irradiation and cyclosporine prolongs cardiac allograft survival in the sensitized rat model. 
  • Total lymphoid irradiation for cardiac xenotransplantation in nonhuman primates. 
  • Transplantation of rat insulinoma allografts with cyclosporin A. 
  • Transplantation of the entire small bowel in inbred rats using cyclosporine. 
  • Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. 
  • Treatment of adult acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host disease, relapse, and relapse-free survival. 
  • Treatment of human acute graft-versus-host disease with antithymocyte globulin and cyclosporine with or without methylprednisolone. 
  • Use of OKT3 in kidney, pancreas, and liver transplantation. 
  • What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants? 
  • Xenograft survival in two species combinations using total-lymphoid irradiation and cyclosporine.